Filtered By:
Source: American Heart Journal
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 491 results found since Jan 2013.
Which risk score best predicts perioperative outcomes in nonvalvular atrial fibrillation patients undergoing noncardiac surgery?
Background: Patients with nonvalvular atrial fibrillation (NVAF) are at increased risk for adverse events after noncardiac surgery. The Revised Cardiac Index (RCI) is commonly used to predict perioperative events; however, the prognostic utility of NVAF risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2) has not been evaluated in patients undergoing noncardiac surgery.Methods: Using a population-based data set of NVAF patients (n = 32,160) who underwent major or minor noncardiac surgery between April 1, 1999, and November 30, 2009, in Alberta, Canada, we examined the incremental prognostic value of the CHADS2, CHA2DS2-VASc, a...
Source: American Heart Journal - April 7, 2014 Category: Cardiology Authors: Sean van Diepen, Erik Youngson, Justin A. Ezekowitz, Finlay A. McAlister Tags: Electrophysiology Source Type: research
Clinical outcomes of hybrid coronary revascularization versus coronary artery bypass surgery in patients with diabetes mellitus
Background: Hybrid coronary revascularization (HCR) involves minimally invasive left internal mammary artery to left anterior descending coronary artery grafting combined with percutaneous coronary intervention (PCI) of non–left anterior descending vessels. The safety and efficacy of HCR among diabetic patients are unknown.Methods: Patients with diabetes were included who underwent HCR at a US academic center between October 2003 and September 2013. These patients were matched 1:5 to similar patients treated with coronary artery bypass grafting (CABG) using a propensity score (PS)-matching algorithm. Conditional logistic...
Source: American Heart Journal - July 14, 2014 Category: Cardiology Authors: Ralf E. Harskamp, Patrick F. Walker, John H. Alexander, Ying Xian, Henry A. Liberman, Robbert J. de Winter, Thomas A. Vassiliades, Eric D. Peterson, John D. Puskas, Michael E. Halkos Tags: Diabetes and Metabolism Source Type: research
Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Source: American Heart Journal - June 7, 2014 Category: Cardiology Authors: Shinya Goto, Jun Zhu, Lisheng Liu, Byung-Hee Oh, Daniel M. Wojdyla, Philip Aylward, M. Cecilia Bahit, Bernard J. Gersh, Michael Hanna, John Horowitz, Renato D. Lopes, Lars Wallentin, Denis Xavier, John H. Alexander, ARISTOTLE Investigators Source Type: research
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct
Conclusions Comprehensive procedures were used for rigorous event reascertainment and readjudication in a previously completed open-label, global clinical trial. These procedures used in this unique situation were consistent with other common approaches in the field, were enhanced to address the FDA concerns about the original RECORD trial results, and could be considered by clinical trialists designing event readjudication protocols for drug development programs that have been completed.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Conclusions Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
Conclusions We observed no interaction between vorapaxar and clopidogrel after non–ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism.
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research
Comparison of Different Inter-dialytic Intervals Among Hemodialysis Patients on Their Echocardiogram-Based Cardiovascular Parameters
Conclusions In a selective Japanese outpatient population on maintenance hemodialysis, there were no differences in resting cardiovascular function measured by echocardiography at three different IDTs. However, exercise-induced afterload mismatch assessed by the changes in Ea, SV, SW and SW/PVA efficiency was most pronounced in individuals following the long IDT compared with other IDTs. Our findings report potential pathophysiologic echocardiographic parameters that attempt to explain why cardiovascular events are highest on the day after the long IDT compared to other IDTs in dialysis patients.
Source: American Heart Journal - February 13, 2015 Category: Cardiology Source Type: research
Patients’ Time in Therapeutic Range on Warfarin Among U.S. Atrial Fibrillation Patients: Results from ORBIT-AF Registry
Conclusions Among AF patients in US clinical practices, TTR on warfarin is suboptimal and those at highest predicted risks for stroke and bleeding were least likely to be in therapeutic range.
Source: American Heart Journal - April 3, 2015 Category: Cardiology Source Type: research
Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality
Conclusions Large increases or sustained elevations in hs-CRP over a six-year period were associated with a subsequent increased risk of diabetes; and persons with sustained elevations in hs-CRP were at the highest risk of CVD and mortality. Two measurements of hs-CRP are better than one for characterizing risk and large increases are particularly prognostic.
Source: American Heart Journal - April 22, 2015 Category: Cardiology Source Type: research
Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry
Conclusions Among patients with AF in US clinical practices, TTR on warfarin is suboptimal, and those at highest predicted risks for stroke and bleeding were least likely to be in therapeutic range.
Source: American Heart Journal - April 23, 2015 Category: Cardiology Source Type: research
Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in atrial fibrillation patients
Conclusions Urinary 11-dehydro-TxB2 levels are associated with a residual risk of CVEs and CV mortality in AF patients despite anticoagulant treatment.
Source: American Heart Journal - May 23, 2015 Category: Cardiology Source Type: research
Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: from the ACCOAST study
Conclusions In ACCOAST, early (<2.98 days) surgical revascularization carried increased risk of bleeding and ischemic complications without affecting all-cause mortality through 30 days. Baseline troponin and prasugrel pretreatment did not impact ischemic clinical outcomes.
Source: American Heart Journal - July 30, 2015 Category: Cardiology Source Type: research
Corrigendum to: Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER): Implementing the patient-driven research paradigm to aid decision making in stroke care
Publication date: Available online 21 July 2015 Source:American Heart Journal Author(s): Ying Xian
Source: American Heart Journal - July 30, 2015 Category: Cardiology Source Type: research
Rationale and Design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients with Multivessel Coronary Artery Disease
Conclusion The FAME 3 study will compare in a multicenter, randomized fashion FFR-guided PCI with contemporary drug-eluting stents to CABG in patients with three-vessel coronary artery disease.
Source: American Heart Journal - July 30, 2015 Category: Cardiology Source Type: research
